蛋白激酶B在肾细胞癌中表达及其功能的研究进展

Research Progress on the Expression and Function of AKT in Renal Cancer Cells

肾细胞癌(renal cell caricinoma,RCC)作为最常见的肾脏恶性肿瘤,约占肾脏恶性肿瘤的90%。肾癌发病率近年来有上升趋势,早期肾癌患者可以通过手术达到良好的治疗效果,晚期患者由于缺乏有效的治疗手段,预后较差。靶向治疗是晚期肾癌的一线治疗方案,但长期的靶向治疗容易出现耐药以及带来副反应。因此,需要探索新的肾癌特异性治疗靶点来优化晚期肾癌治疗方案。蛋白激酶B(protein kinase B,AKT)作为磷脂酰肌醇3-激酶(phosphatidylinositol 3-kinase,PI3K)在PI3K/AKT/mTOR信号通路中的效应分子,一旦激活,能调节许多下游蛋白的功能,这些下游蛋白涉及细胞生存、增殖、迁移、凋亡等,AKT信号通路在各种癌症的发病机制中起着重要作用。以往的研究发现AKT与肾癌的发生发展关系密切,对肾癌的诊疗工作及新型靶向治疗药物的研发中具有巨大的潜在价值。论文对AKT在肾细胞癌中表达及其作用的研究进展统一综述。

Renal cell carcinoma(RCC),the most common renal malignant tumor,accounts for about 90%of renal malignant tumors.The incidence of RCC has an going up trend in recent years.Early stage of RCC could be cured with surgery.The prognosis of late stage cancer was poor due to lack of effective treatment.Target therapy is the first-line treatment for local advanced and metastatic RCC,however,long-term target therapy would induced drug resistance and side effects.Which need to find a novel specific therapeutic targets of advanced RCC.AKT(protein kinase B),an effector molecule of phosphatidylinositol 3-kinase(PI3 K)in PI3 K/AKT/mTOR signaling pathway,can regulate the function of many downstream proteins,involved in cell survival,proliferation,migration and apoptosis.Previous studies had found that AKT signaling pathway plays an important role in the pathogenesis of many cancers,including clear cell renal cell carcinoma.AKT has great potential value in diagnosis and treatment of RCC and target therapy.In this article,we reviewed the research progress of AKT expression and its role in RCC.